Refractory Lymphoplasmacytic Lymphoma

Explore clinical trials studying Refractory Lymphoplasmacytic Lymphoma. Study availability and eligibility vary by location and protocol.

9 public trials 1 recruiting study

Refine in advanced search Browse all conditions

Refractory Lymphoplasmacytic Lymphoma trial results

Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

NCT06712810

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, Bone Marrow Diseases, +87 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

NCT02332980

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +48 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Completed

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

NCT04578600

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +39 more
Locations: University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View Trial Details

Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00723099

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
Locations: University of Colorado Hospital Aurora, Colorado, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

LDS Hospital Salt Lake City, Utah, United States

VA Puget Sound Health Care System Seattle, Washington, United States

View Trial Details

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT02950220

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Active, Not Recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations: University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada

View Trial Details

Active, Not Recruiting

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

NCT03479268

Conditions: B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
Locations: City of Hope Medical Center Duarte, California, United States

Roswell Park Comprehensive Cancer Center Buffalo, New York, United States

View Trial Details

Active, Not Recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT03015896

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
Locations: Emory University Atlanta, Georgia, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Refractory Lymphoplasmacytic Lymphoma

Refractory Lymphoplasmacytic Lymphoma trial results

Related conditions